5000th patient treated with protons for eye tumours
From the patient's perspective at the treatment station: The proton beam is directed through the hole in the shield onto the tumour in the eye. The brass shield is adjusted to the individual tumour size and protects the surrounding tissue. © HZB/. S. Kodalle
The treatment centre for eye tumour therapy in Berlin-Wannsee © HZB/ S. Kodalle
For more than 25 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.
The treatment room and proton accelerator are specially adapted to the requirements for optimal and highly precise treatment of tumours inside the eye and are unique in this combination. The largest group of tumours in the eye is the rare and malignant uveal melanoma, which, as the name suggests, develops in the uvea of the eye.
Proton therapy is used as an effective method of fighting tumours, often as an alternative to removing the eye, with the aim of preserving the eye and its function as much as possible. The protons can be directed very precisely at the tumour, sparing the surrounding healthy tissue. Compared to other radiation methods, proton therapy causes less damage to the cornea, lens, retina and optic nerve in many cases.
8 August 2025 was a special day: it was the day on which the 5000th patient completed their eye tumour treatment. This makes the Berlin experts one of the world's leading centres: together, the two institutions (Charité and HZB) have treated 10 percent of all eye tumours treated with protons worldwide. The cooperation with Charité – Universitätsmedizin Berlin also opens up prospects for the further development of proton therapy in order to carry out even more precise and effective treatments in the future – for the benefit of patients.
- Perovskite solar cells: Predictions of long-term stabilityReliable statements about the long-term stability of perovskite solar cells are still difficult to make. However, a new study by Dr Carolin Ulbrich’s team, published in the renowned journal Joule, highlights which methods are useful for this purpose and identifies areas where further research is needed.
- Superconducting TES array X-ray spectrometer goes into operation at BESSY IIEurope's first and only TES-spectrometer at a synchrotron source is now in operation at BESSY II, developed within a collaboration between the HZB, the MPI-CEC (Mühlheim-an-der-Ruhr, Germany) and the NIST (Boulder CO, USA). The photon detection efficiency of the new instrument exceeds that of wavelength-dispersive X-ray emission spectrometers by a factor of 100 to 1000. It will be used to investigate the electronic properties of atomically thin layers, nanostructures and highly diluted atomic and molecular samples. The team is looking forward to receiving exciting research proposals from the user community.
- A New Era in Catalysis: ASCEND Launch in Berlin, €30 Million in FundingOn 11 June 2026, the Helmholtz-Zentrum Berlin (HZB) in Adlershof hosted the launch of ASCEND (Accelerated Solutions for Catalysis using Emerging Nanotechnology and Digital Innovation). The event took place in the presence of the Minister of Research, Dorothee Bär, President of the Helmholtz Association, Prof. Dr. Martin Keller, and President of the Max Planck Society, Prof. Dr. Patrick Cramer. Bringing together leading partners from industry and research, ASCEND is supported by BMFTR with €30 million in funding and officially started on 1 April 2026. The initiative aims to accelerate the discovery of next-generation catalysts and enable more sustainable chemical processes.